Delving into the Latest Updates on Arginine glutamate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-amino-5-(diaminomethylideneamino)pentanoic acid, 2-amino-5-guanidino-pentanoic acid, 2-aminoglutaric acid

+ [8]

Target-

Action-

Mechanism-

Therapeutic Areas

Other DiseasesNervous System DiseasesDigestive System Disorders+ [1]

Active Indication

HyperammonemiaHepatic Encephalopathy

Inactive Indication

Chronic liver disease

Originator Organization

AY Pharmaceuticals Co Ltd.

Active Organization

Furen Medicines Group Co., Ltd.

AY Pharmaceuticals Co Ltd.

Liaoning Haisco Pharmaceutical Co., Ltd.

Inactive Organization

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (18 Nov 1960),

Hyperammonemia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC11H23N5O6

InChIKeyRVEWUBJVAHOGKA-WOYAITHZSA-N

CAS Registry4320-30-3

exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction
cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal model by L-arginine supplementation
to determine the potential beneficial effect of L-arginine supplementation on exercise capacity and renal function of heart transplant recipients

Start Date01 Feb 2004

Sponsor / Collaborator

Les Hopitaux Universitaires de Strasbourg

100 Clinical Results associated with Arginine glutamate

Login to view more data

100 Translational Medicine associated with Arginine glutamate

Login to view more data

100 Patents (Medical) associated with Arginine glutamate

Login to view more data

102

Literatures (Medical) associated with Arginine glutamate

01 Mar 2025·Journal of Colloid and Interface Science

Zn2+ flux regulator to modulate the interface chemistry toward highly reversible Zn anode

Article

Author: Chen, Dongping ; Yu, Huaming ; Xie, Zeqiang ; Zhang, Chi ; Kang, Chao ; Zhou, Jie ; Li, Canglong ; He, Zhongqian ; Chen, Yuejiao ; Cheng, Yuanzi ; You, Tiancheng

The persistent challenges of diminished coulombic efficiency (CE) and the formation of Zn dendrites at the Zn anode interface substantially hinder the cycle life of aqueous Zn-ion batteries (AZIBs), thereby impeding their widespread deployment. To address these issues, multifunctional 2-amino-5-guanidino-pentanoic acid (AGPA) additive is introduced into the electrolyte, as a novel Zn²⁺ flux regulator (ZFR) to improve the reversibility and durability of Zn anodes. The distinctive zincophilicity of amino groups empowers such ZFR with a higher adsorption energy, enabling the construction of a multifunctional molecular adsorption layer on Zn electrode surface. Simultaneously, leveraging the exceptional nucleophilic characteristics of polar carboxyl groups, AGPA molecules tend to form chelating bonds with Zn²⁺ for manipulating the interface chemistry and solvation chemistry. The functional groups in ZFR work in synergy to attract zinc ions for homogenizing Zn²⁺ flux and suppress the interfacial side reactions, resulting in uniform dendrite-free Zn deposition. Consequently, the Zn//Zn symmetrical cell achieves an extended cycle life of 5500 h. Moreover, the ZFR enables stable operation of the full batteries with an ultra-long cycling lifespan of 6000 cycles at 5 A/g, showcasing the effectiveness of ZFR in advancing the commercialization of AZIBs.

01 Aug 2024·Journal of Pharmaceutical Sciences

Designing Robust Monoclonal Antibody Drug Products: Pitfalls of Simplistic Approaches for Stability Prediction

Article

Author: Gokarn, Yatin R ; Saluja, Atul ; Rembert, Kelvin B

Thermal stability attributes including unfolding onset (T_onset) and mid-point (T_m) are often utilized for efficient development of monoclonal antibody (mAb) products during lead selection and formulation screening workflows. An assumption of direct correlation between thermal and kinetic physical stability underpins this basic approach. While literature reports have substantiated this general approach under specific conditions, clear exceptions have been highlighted alongside. Herein, a set of mAbs formulated under diverse solution conditions to generate a broad array of thermal and kinetic stability profiles were systematically analyzed. Sequence modifications in the Fc region were purposefully engineered to generate a set of low-melting mAbs. A diverse set of excipients were subsequently utilized and shown to modulate the T_m over a wide range. While a general correlation between high T_m and low aggregation rate was observed under accelerated conditions, the predictive utility of T_m under relevant product storage conditions was inadequate at best. Critically, T_m data did not correlate with long-term aggregation rates under refrigerated or room temperature conditions. Even under accelerated conditions, T_m appeared to be a poor predictor of aggregation once it exceeded the solution storage temperature (40°C) by ∼15°C, similar to conditions routinely encountered in the development of canonical mAbs (T_m > 60°C). Pitfalls of simplistic correlative approaches are discussed in the context of practical biologics product development.

01 May 2022·International Journal of PharmaceuticsQ2 · MEDICINE

Role of arginine salts in preventing freezing-induced increase in subvisible particles in protein formulations

Q2 · MEDICINE

Article

Author: Patel, Sajal M ; Suryanarayanan, Raj ; Munjal, Bhushan

While arginine hydrochloride (ArgHCl) has emerged as a potential stabilizer of protein drugs in liquid formulations, the purpose of this manuscript was to evaluate its stabilization potential in frozen solutions. The phase behavior of frozen ArgHCl solutions was investigated by differential scanning calorimetry and low temperature powder X-ray diffractometry. The aggregation of β-galactosidase was evaluated following freeze-thaw cycling in ArgHCl solutions with and without mannitol. ArgHCl (5% w/v) was retained amorphous in frozen aqueous solutions and effectively inhibited protein aggregation even after 5 freeze-thaw cycles. Annealing frozen arginine solution (5% w/v) containing mannitol (10% w/v) induced mannitol crystallization which in turn facilitated crystallization of ArgHCl. The stabilizing effect of ArgHCl was completely lost in the presence of mannitol. Use of alternate arginine salts (aspartate, glutamate, and acetate) allowed selective crystallization of mannitol while arginine was retained amorphous and stabilized the protein.

100 Deals associated with Arginine glutamate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02397	Arginine glutamate	A05BA01	DB13207

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperammonemia	Japan	AY Pharmaceuticals Co Ltd.	18 Nov 1960

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatic Encephalopathy	Phase 1	China	Furen Medicines Group Co., Ltd.	13 Nov 2013
Chronic liver disease	Discovery	China	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	12 Apr 2013
Hyperammonemia	Discovery	China	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	12 Apr 2013